loading page

Hypersensitivity Reactions to Biologicals: an EAACI position paper
  • +6
  • Sevim Bavbek,
  • Mauro Pagani,
  • Emilio Alvarez-Cuesta,
  • Mariana Castells,
  • Adile Berna Dursun,
  • Sahar Hamadi,
  • Ricardo Madrigal-Burgaleta,
  • Soledad Sanchez-Sanchez,
  • Alessandra Vultaggio
Sevim Bavbek
Ankara University Faculty of Medicine
Author Profile
Mauro Pagani
ASST Mantova
Author Profile
Emilio Alvarez-Cuesta
Hospital Ramón y Cajal
Author Profile
Mariana Castells
Brigham and Women's Hospital
Author Profile
Adile Berna Dursun
Recep Tayyip Erdoğan University
Author Profile
Sahar Hamadi
Division of Immunology and Allergy; Department of Medicine, Brigham and Women’s Hospital
Author Profile
Ricardo Madrigal-Burgaleta
St Bartholomew's Hospital, Barts Health NHS Trust
Author Profile
Soledad Sanchez-Sanchez
University Hospital Complex A Coruña (CHUAC),
Author Profile
Alessandra Vultaggio
Azienda Ospedaliera Universitaria Careggi,
Author Profile

Abstract

Because of their selectivity, biologicals are crucial therapeutic agents in oncological, immunological, and inflammatory diseases and their use in clinical practice is broadening. Biologicals are among the most common drugs that can cause hypersensitivity reactions (HSRs), and this is primarily attributed to an explosion in new treatment options that has developed through personalized and precision medicine. Patients can develop HSRs to these agents during the first lifetime exposure or after repeated exposure. Despite its relatively high prevalence, the underlying mechanisms and optimal management of HSRs to biologicals remain incompletely explained. In this position paper, the authors provided evidence-based recommendations for the diagnosis and management of HSRs to biologicals. Additionally, the document defines unmet needs, which should be topics of future studies.

Peer review status:ACCEPTED

29 Mar 2021Submitted to Allergy
30 Mar 2021Submission Checks Completed
30 Mar 2021Assigned to Editor
31 Mar 2021Reviewer(s) Assigned
12 Apr 2021Review(s) Completed, Editorial Evaluation Pending
12 Apr 2021Editorial Decision: Revise Minor
30 May 20211st Revision Received
01 Jun 2021Submission Checks Completed
01 Jun 2021Assigned to Editor
02 Jun 2021Reviewer(s) Assigned
14 Jun 2021Review(s) Completed, Editorial Evaluation Pending
15 Jun 2021Editorial Decision: Accept